The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index; 15 of the 127 sources its claims cite were checked for support.
Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers
Open accessAbstract
Lipids are a crucial component of the human brain, serving important structural and functional roles. They are involved in cell function, myelination of neuronal projections, neurotransmission, neural plasticity, energy metabolism, and neuroinflammation. Despite their significance, the role of lipids in the development of mental disorders has not been well understood. This review focused on the potential use of lipids as blood biomarkers for common mental illnesses, such as major depressive disorder, anxiety disorders, bipolar disorder, and schizophrenia. This review also discussed the impact of commonly used psychiatric medications, such as neuroleptics and antidepressants, on lipid metabolism. The obtained data suggested that lipid biomarkers could be useful for diagnosing psychiatric diseases, but further research is needed to better understand the associations between blood lipids and mental disorders and to identify specific biomarker combinations for each disease.
Overview
CoChat Summary
TL;DR
This narrative review summarizes evidence that blood lipid classes are altered across major depressive disorder, anxiety disorders, bipolar disorder, and schizophrenia, and that antipsychotics and antidepressants themselves affect lipid metabolism. It concludes that lipid biomarkers may aid diagnosis and prognosis, but associations remain incompletely understood and specific diagnostic combinations are not yet established.
Key findings
- Across reviewed studies, the most consistent schizophrenia findings were reductions in phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SM), and triacylglycerols (TGs); malondialdehyde was increased in all concerned studies, and HDL was decreased in two studies.
- In major depressive disorder, lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE) were increased, while acylcarnitine (CAR), calcifediol, SM, and bile acids were mostly decreased; PC and malondialdehyde were mostly elevated.
- In anxiety disorders, almost all reviewed papers reported increased TGs, and polyunsaturated fatty acids (PUFAs) were mainly decreased; malondialdehyde was increased, while 20-oxo-22,23,24,25,26,27-hexanorvitamin D3 was decreased.
- One transdiagnostic study suggested 10 lipids could be used for diagnostics across psychiatric disorders; CAR and SM were decreased across all reviewed psychiatric disorders, and malondialdehyde was increased across all.
- Medication effects were prominent: typical and atypical antipsychotics increased cholesterol, TG, and LDL, with olanzapine and clozapine showing the worst side-effect profiles and aripiprazole, brexiprazole, cariprazine, lurasidone, and ziprasidone the most favorable; several studies found selective serotonin reuptake inhibitors increased TC, TGs, and LDL in depressed patients.
Methods
- Narrative review of blood lipid biomarkers in schizophrenia (SCZ), bipolar disorder (BPD), major depressive disorder (MDD), and anxiety disorders (AD), plus a section on antipsychotic and antidepressant effects on lipid metabolism.
- The authors summarized studies in Table S1 and Table 1, reporting over 29 SCZ studies, 19 MDD studies, 14 BPD studies, and 24 AD studies; only nine SCZ studies, four MDD studies, and six AD studies involved more than 100, 100, and 300 individuals, respectively.
- No new primary data or meta-analysis were reported; findings are synthesized from the cited literature, including broad lipidomic panels and specific lipid classes.
Limitations
- Stated: further research is needed to better understand associations between blood lipids and mental disorders and to identify specific biomarker combinations for each disease.
- Stated: most studies did not compare patients with diagnosed depression after treatment against a healthy control group, making it difficult to assess whether antidepressants affect lipid metabolism and restore normal lipid profiles.
- Evident from the text: many findings were inconsistent or multidirectional (e.g., PUFAs, Cers, TGs, cholesterol, and lipoproteins), several studies were small, and psychopharmacologic treatment is a major confounding factor for lipidome measurements.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
11 Valid · 4 Not valid · 84 Not checked · 30 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Elevated glucocorticoid levels increase phospholipase D activity [35].”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
What the sources say
- Supportedcites [35] Walther, 2018, Lipidomics in Major Depressive Disorder, Front. Psychiatry source
The Figure 2 legend ('The lipidome in MDD', p. ~7) states outright: 'Increased levels of glucocorticoids increase PLD activity.' The main text ('Lipidome associations with glucocorticoids and inflammatory markers', p. ~6) supports this with the in vitro finding that dexamethasone-treated M-1 cells express higher phospholipase D activity, hydrolyzing PC to PA. The claim reproduces the source's own general statement, so it is supported; the underlying experimental basis is a glucocorticoid (dexamethasone) cell-culture study (ref. 48, Kim et al., 2000), which this review reports and incorporates into its pathway model. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Nine studies evaluated the broad panels of different lipid markers in patients with SCZ [31,34,40,41,42,43,44,45,46] and detected statistical differences in the following lipid classes: fatty acyls, sterols, glycerolipids, sphingolipids, glycerophospholipids, and products of lipid metabolism.”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
What the sources say
- Not checked yetcites [31] Li, 2022, Impaired Membrane Lipid Homeostasis in Schizophrenia, Schizophr. Bull. source
- Supportedcites [34] Wang, F., Guo, L., Zhang, T., Cui, Z., Wang, J., Zhang, C., Xue, F., Zhou, C., Li, B., and Tan, Q. (2022). Alterations in Plasma Lipidomic Profiles in Adult Patients with Schizophrenia and Major Depressive Disorder. Medicina, 58. source
This citation identifies one of the nine studies, not a source for the count of nine or every lipid class listed across them. The Introduction describes a case-control study of adults with schizophrenia using plasma lipidomics, and Results §3.2 reports analysis of 30 lipid classes and 782 species, with statistically significant differences in several classes. (LLM, conf=0.92)
- Not checked yetcites [40] Liu, 2021, Alteration of Lipids and Amino Acids in Plasma Distinguish Schizophrenia Patients from Controls: A Targeted Metabolomics Study, Psychiatry Clin. Neurosci. source
- Supportedcites [41] Tkachev, A., Stekolshchikova, E., Anikanov, N., Zozulya, S., Barkhatova, A., Klyushnik, T., and Petrova, D. (2021). Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia. Biomolecules, 11. source
The Results (§3.1; page unavailable) report that this study assessed 322 plasma lipid species across 14 classes in patients with schizophrenia. Results (§3.2; page unavailable) report statistically significant changes in 22 lipids among patients with the least symptom improvement, including 20 triglycerides. The citing sentence attributes the full list of lipid classes to nine studies collectively, not to this study alone. (LLM, conf=0.88)
- Not checked yetcites [42] Yan, 2018, Unbiased Lipidomic Profiling Reveals Metabolomic Changes during the Onset and Antipsychotics Treatment of Schizophrenia Disease, Metabolomics source
- Supportedcites [43] Sun, 2012, Phospholipids and Insulin Resistance in Psychosis: A Lipidomics Study of Twin Pairs Discordant for Schizophrenia, Genome Med. source
The Results section (page unavailable) reports a broad lipidomics panel of 530 measured lipids in patients with schizophrenia and comparison groups. Table 2 reports a significant patient–co-twin difference for a triglyceride cluster (P = 0.039). This supports citing the paper as one of the studies in the group; the six lipid classes are presented as the studies’ collective findings, not as findings of this paper alone. (LLM, conf=0.87)
- Supportedcites [44] Costa, A.C., Riça, L.B., van de Bilt, M., Zandonadi, F.S., Gattaz, W.F., Talib, L.L., and Sussulini, A. (2023). Application of Lipidomics in Psychiatry: Plasma-Based Potential Biomarkers in Schizophrenia and Bipolar Disorder. Metabolites, 13. source
This paper is one of the studies cited in the nine-study list. Its Results (§3.1–3.2; page unavailable) report statistically significant features in the schizophrenia comparisons and differential lipids spanning fatty acids, sterols, glycerolipids, sphingolipids, and glycerophospholipids; §3.2 also examines lipid-metabolism pathways. It supports its inclusion as an example, rather than independently establishing the total of nine studies. (LLM, conf=0.88)
- Not checked yetcites [45] Wang, 2021, Characterising Phospholipids and Free Fatty Acids in Patients with Schizophrenia: A Case-Control Study, World J. Biol. Psychiatry source
- Not checked yetcites [46] Wang, 2019, Metabolic Profiling Identifies Phospholipids as Potential Serum Biomarkers for Schizophrenia, Psychiatry Res. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The levels of PC and PE did not differ significantly in FEP patients and medicated patients [53,54].”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
What the sources say
- Partly supportedcites [53] McEvoy, J., Baillie, R.A., Zhu, H., Buckley, P., Keshavan, M.S., Nasrallah, H.A., Dougherty, G.G., Yao, J.K., and Kaddurah-Daouk, R. (2013). Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics. PLoS ONE, 8. sourceExperimental — accuracy not yet measured
The Results (Metabolic Signature of Disease; page unavailable) report that first-episode (FE) and recurrent-episode (RE) patients differed significantly in PE n3 concentrations, but not in the other PC and PE n3/n6 concentrations assessed. Thus, the blanket claim of no significant difference in both PC and PE is too broad. The comparison was between FE and RE groups at baseline, not explicitly between first-episode and currently medicated patients. (LLM, conf=0.87)
- Not checked yetcites [54] McEvoy, 2012, Impaired Plasmalogens in Patients with Schizophrenia, Psychiatry Res. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Increased saturated fatty acid-rich phospholipids, namely lysoPS (16:0), lysoPS (18:0), and SM (24:0), have been associated with inflammation and oxidative stress responses in depressed patients [35].”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
What the sources say
- Partly supportedcites [35] Walther, 2018, Lipidomics in Major Depressive Disorder, Front. Psychiatry sourceExperimental — accuracy not yet measured
The Human studies and The lipidome in MDD sections describe links between altered lipids and inflammation in depression, including phospholipids that release proinflammatory compounds. They do not report increased lysoPS (16:0), lysoPS (18:0), or SM (24:0), or associate those specific lipids with oxidative stress responses in depressed patients (pages unavailable in our copy). (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Antipsychotic drugs produce metabolic side effects with a different extent depending on their type.”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 3. Effect of Medications on Lipid Metabolism > 3.1. Antipsychotics
What the sources say
- Supportedcites [131] Pillinger, 2020, Comparative Effects of 18 Antipsychotics on Metabolic Function in Patients with Schizophrenia, Predictors of Metabolic Dysregulation, and Association with Psychopathology: A Systematic Review and Network Meta-Analysis, Lancet Psychiatry source
The Discussion states that metabolic side-effects vary markedly between antipsychotics, identifying olanzapine and clozapine as having the worst profiles and several others as having the best. This directly supports the claim that the extent of metabolic side-effects depends on the drug. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
80 more claims · 6 with their cited sources checked
Create a free account to see all 129 claims and to verify the 112 references still open.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 37
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lipids are integral to cellular processes, including neurotransmission, neuroplasticity, neural projection myelination, energy metabolism, and neuroinflammation (29).”
From Retrospective evaluation of novel serum inflammatory biomarkers in first-episode psychiatric disorders: diagnostic potential and immune dysregulation (2024) · doi:10.3389/fpsyt.2024.1442954 · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
“Among the addressed studies, one was dedicated to the transdiagnostic lipid markers between four illnesses: MDD, BPD, AD, and SCZ [79].”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > References
“79. Tao S. Zhang Y. Wang Q. Qiao C. Deng W. Liang S. Wei J. Wei W. Yu H. Li X. Identifying Transdiagnostic Biological Subtypes across Schizophrenia, Bipolar Disorder, and Major Depressive Disorder Based on Lipidomics Profiles”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
“Unidirectional changes were detected when studying the levels of 20-oxo-22,23,24,25,26,27-hexanorvitamin D3 and malondialdehyde.”
§ Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers > 2. Lipids and Their Role in Neuropsychiatric Disorders
“Thus, decreased levels of 20-oxo-22,23,24,25,26,26,27-hexanorvitamin D3 accompanied anxiety symptomatology [76,77].”
Citations
Cites
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30416-x · Cited by 1,090
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581 · cited 1×
“Once abnormalities are detected, complex remodeling of the lipid composition of microglial cells occurs, providing inflammatory signaling and effector functions [26].”
BackgroundBrain lipidomics: From functional landscape to clinical significance
Yoon, J. H., Seo, Y., Jo, Y. S., Lee, S., Cho, E., Cazenave-Gassiot, A., Shin, Y.-S., Moon, M. H., An, H. J., Wenk, M. R., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9317 · Cited by 324
Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002000 · Cited by 262 · cited 1×
“Among others, neuroleptic therapy affects lipid homeostasis [130,131].”
BackgroundMembrane Lipids in Presynaptic Function and Disease
Lauwers, E., Goodchild, R., & Verstreken, P. (2016) · Neuron · doi:10.1016/j.neuron.2016.02.033 · Cited by 229
Fatty Acids in Energy Metabolism of the Central Nervous System
Panov, A., Orynbayeva, Z., Vavilin, V., & Lyakhovich, V. (2014) · BioMed Research International · doi:10.1155/2014/472459 · Cited by 227
Liu, X., Zheng, P., Zhao, X., Zhang, Y., Hu, C., Li, J., Zhao, J., Zhou, J., Xie, P., & Xu, G. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00144 · Cited by 193
Membrane changes under oxidative stress: the impact of oxidized lipids
Itri, R., Junqueira, H. C., Mertins, O., & Baptista, M. S. (2014) · Biophysical Reviews · doi:10.1007/s12551-013-0128-9 · Cited by 191
Zhou, X., Liu, L., Lan, X., Cohen, D., Zhang, Y., Ravindran, A. V., Yuan, S., Zheng, P., Coghill, D., Yang, L., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0047-z · Cited by 181
Cited by
(2024) · doi:10.3389/fpsyt.2024.1442954 · Cited by 15
Wang, Y., Chen, H., Wang, J., Chen, S., Liu, J., Chen, X., Li, S., Tang, H., Zhou, J., Ye, Y., et al. (2025) · Depression and Anxiety · doi:10.1155/da/5564796 · Cited by 15
Neural Spectral Prediction for Structure Elucidation with Tandem Mass SpectrometryPreprint
Wang, R., Manjrekar, M., Mahjour, B. A., Ávila-Pacheco, J., Provenzano, J., Reynolds, E. E., Lederbauer, M., Mashin, E., Goldman, S., Wang, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.28.656653 · Cited by 19
Bisle, E., Haange, S., Rojas, R., Behnke, A., Karabatsiakis, A., Gumpp, A. M., Mack, M., Mavioğlu, R. N., Lutz‐Bonengel, S., Rolle-Kampczyk, U. E., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116569 · Cited by 10
Ungur, A. P., Socaciu, A. I., Bârsan, M., Râjnoveanu, A. G., Ionuţ, R., Socaciu, C., & Procopciuc, L. M. (2025) · Clocks & Sleep · doi:10.3390/clockssleep7030036 · Cited by 6
Metadata
- Authors
- Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., Kostyuk, G., & Morozova, A.
- Affiliations
- Federal Medical Research Centre for Psychiatry and Narcology (RU)
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
- Moscow Center for Healthcare Innovations, 123473 Moscow, Russia
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academi of Science, 142290 Moscow, Russia
- Corresponding author
- Zorkina, Yana
- ORCID
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2024-01-23
- Volume
- 14
- Issue
- 2
- Pages
- 80
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC10890164
- OpenAlex
- W4391131005
- Semantic Scholar
- e228f4240ba3c715551466152dfa01310093988b
- Cited by
- 36
- References
- 157
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 4
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Moscow Center for Innovative Technologies in Healthcare (2707-2/22)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- serum lipids, lipid biomarkers, mental illness, major depressive disorder, anxiety disorders, bipolar disorder, schizophrenia, lipid metabolism, antipsychotic drugs, antidepressants, neuroinflammation, psychiatric diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers. https://app.cochat.ai/papers/10.3390/metabo14020080
- The paper
- Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., Kostyuk, G., & Morozova, A. (2024). Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers. Metabolites. https://doi.org/10.3390/metabo14020080
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

